HER2-Low Breast Cancer: Pathological and Clinical Landscape.
暂无分享,去创建一个
F. Cardoso | F. Penault-Llorca | F. André | G. Curigliano | G. Viale | S. Tolaney | J. Cortés | P. Tarantino | D. Trapani | E. Ferraro | S. Morganti | E. Hamilton | A. Marra | G. Viale | Giuseppe A. Viale | Giulia Viale | Giuseppe Viale
[1] K. Nakagawa,et al. [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification , 2019, International journal of cancer.
[2] E. D. de Vries,et al. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. , 2019, Pharmacology & therapeutics.
[3] F. Cardoso,et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] P. Parren,et al. Bispecific antibodies: a mechanistic review of the pipeline , 2019, Nature Reviews Drug Discovery.
[5] M. Piccart,et al. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review , 2019, Current Treatment Options in Oncology.
[6] G. Peoples,et al. Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. , 2019, Clinical immunology.
[7] R. Greil,et al. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer , 2019, International journal of molecular sciences.
[8] J. Cuzick,et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[10] N S El Saghir,et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] M. Piccart,et al. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. , 2018, Cancer treatment reviews.
[12] A. Schneeweiss,et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer , 2018, Investigational New Drugs.
[13] G. Doherty,et al. Activating HER2 mutations as emerging targets in multiple solid cancers , 2017, ESMO Open.
[14] James T. Robinson,et al. Variant Review with the Integrative Genomics Viewer. , 2017, Cancer research.
[15] R. Weigel,et al. A novel HER2 gene body enhancer contributes to HER2 expression , 2017, Oncogene.
[16] Jinhua Dong,et al. Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control , 2017, Scientific Reports.
[17] G. Giaccone,et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Helene Dérand,et al. A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2 , 2017, Modern Pathology.
[19] J. Murray,et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence , 2016, Oncotarget.
[20] J. Murray,et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Y. Kamata,et al. Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. , 2015, Oncology reports.
[22] John W. Adams,et al. Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival , 2015, Breast Cancer Research.
[23] E. Mittendorf,et al. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. , 2014, Immunotherapy.
[24] E. Perez,et al. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer , 2014, Breast Cancer Research.
[25] L. Xerri,et al. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases , 2013, BMC Cancer.
[26] R. Ponzone,et al. Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. , 2012, The oncologist.
[27] P. Moore,et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties , 2011, Breast Cancer Research.
[28] M. Espié,et al. Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches , 2011, British Journal of Cancer.
[29] C. Denkert,et al. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765) , 2011, Breast Cancer Research and Treatment.
[30] Jason I. Herschkowitz,et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.
[31] C. Petropoulos,et al. Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark®) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens , 2010, Pathology research international.
[32] D. Rimm,et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. , 2005, Journal of the National Cancer Institute.
[33] R. Nicholson,et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.
[34] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[35] J. Cairns,et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.
[36] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.